Results showed a down-regulation of FXR in NASH and an up-regulation of TGR5 and Iba-1 in the cortex and hippocampus in both treated groups as compared to the control group. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatohepatitis.